Compare ResMed Inc. (RMD) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs AT&T Inc. — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while AT&T Inc. trades at $25.16 (market cap $175.42B). The key difference: AT&T Inc. is far larger — about 5.5× ResMed Inc.'s market cap, and AT&T Inc. pays the higher dividend (4.34%). Which is the better fit depends on your goals.
| RMD | T | |
|---|---|---|
Market Cap | $31.89B | $175.42B |
Sector | Health | Media |
52-Week High | $283.28 | $29.62 |
52-Week Low | $182.82 | $20.49 |
Enterprise Value | $31.24B | $320.74B |
Dividend Yield | 1.19% | 4.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
AT&T (T) trades at $25.61, down 0.21% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 8.45, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent developments include strategic partnerships with Amazon for satellite broadband and continued fiber expansion, positioning the company for growth in the competitive telecom sector.
The outlook for AT&T remains positive with analyst consensus pointing to 8% upside to the $27.69 price target. Key opportunities include fiber infrastructure expansion and wireless network enhancements, while risks involve heavy capital expenditures and competitive pressures. The stock offers value with attractive valuation metrics and dividend yield, supported by improving cash flow trends and debt reduction efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
